AZNCF News and Press, AstraZeneca Plc From 07/29/22

The following slide deck was published by AstraZeneca PLC in conjunction with their 2022 Q2 earnings call. For further details see: AstraZeneca PLC 2022 Q2 - Results - Earnings Call Presentation

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended June 30, 2022, Baron Health Care Fund declined 10.00% compared with the Benchmark. We are partic...

AstraZeneca's operating income was $2,808 million in Q1 2022, up 49.5% QoQ. At the end of June 2022, the CHMP recommended the approval of Enhertu and Lynparza in the EU. Tagrisso sales were $1,304 million in Q1 2022, up 13.5% year-over-year. The total debt/EBITDA ratio decreas...

Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. We are closely watching corporate results to determine the near-term outlook for international equities. How co...

Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. To manage through the myriad uncertainties in the current environment, we continue to rely on secular and struc...

Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. To manage through the myriad uncertainties in the current environment, we continue to rely on secular and struc...

The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names. It's clear (to us) that AUPH should be on the ...

Pfizer's revenue was $25,661 million in Q1 2022, up 76.8% year-over-year. Pfizer's total debt was $36,441 million in Q1 2022, down 12% from the previous quarter. Over the past 12 months, Pfizer has acquired Biohaven Pharmaceuticals and Arena Pharmaceuticals, which has significantl...

At the ASCO meeting, BioNTech presented phase-1 clinical trial data for its mRNA-based vaccine for pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer. AstraZeneca and Daiichi presented data for the Destiny-Breast04 trial, which tested Enhertu against chemother...

Unofficial sources said Joincare would seek to raise around $300 to $400 million. META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. CANbridge, a Beijing-Cambridge MA rare disease/rare on...